Holen Sie sich die Stockscreener-App
16.11
3.30%
-0.55
Schlusskurs vom Vortag:
$16.66
Offen:
$16.36
24-Stunden-Volumen:
279.78K
Relative Volume:
1.22
Marktkapitalisierung:
$2.06B
Einnahmen:
$17.20M
Nettoeinkommen (Verlust:
$-102.16M
KGV:
-19.05
EPS:
-0.8458
Netto-Cashflow:
$-57.32M
1W Leistung:
-3.59%
1M Leistung:
-12.49%
6M Leistung:
+33.69%
1J Leistung:
+89.98%
1-Tages-Spanne:
$15.71
$16.36
1-Wochen-Bereich:
$15.71
$17.00
52-Wochen-Spanne:
$8.34
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
Firmenname
Mesoblast Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MESO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
16.11 | 2.14B | 17.20M | -102.16M | -57.32M | -0.8458 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-12-23 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-24 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-29 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-23 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Eingeleitet | William Blair | Outperform |
| 2022-12-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-06 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-12-22 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-12-04 | Herabstufung | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2020-05-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-31 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-03-22 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2017-06-08 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Mesoblast Ltd Adr Aktie (MESO) Neueste Nachrichten
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch - GlobeNewswire Inc.
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLC - Defense World
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - ADVFN Brasil
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Novagold Resources Inc (NG) Stock: A Year of Decreases and Increases - investchronicle.com
TV’s 2025 Market Dance: Down -20.11% – Time to Invest? - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Cango Inc ADR (CANG) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Innodata Inc (INOD) Stock: A Year of Market Movement, Down and Up - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Burford Capital Limited: Navigating Market Fluctuations with a 3.10B Market Cap - investchronicle.com
Chagee Holdings Ltd. ADR (CHA) Stock: A Year of Highs and Lows - investchronicle.com
Nano X Imaging Ltd (NNOX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
WGRX Stock Update: Wellgistics Health Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
ZTO’s Stock Market Adventure: -5.37% YTD Growth Amidst Volatility - investchronicle.com
MGRX’s Market Whiplash: -74.88% YTD Decline, -16.49% Plunge in 30 Days - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com India
Sonim Technologies Inc (SONM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
An In-Depth Look at Trident Digital Tech Holdings Ltd. ADR Inc. (TDTH) Price Performance During Market Crashes - investchronicle.com
BTCM: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
DallasNews Corporation (DALN) Stock: Uncovering 52-Week Market Trends - investchronicle.com
DraftKings Inc (DKNG) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
TSM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Krispy Kreme Inc (DNUT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd Share Price ADR Each Representing 10 Ord Shares SPON - Hargreaves Lansdown
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
Finanzdaten der Mesoblast Ltd Adr-Aktie (MESO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):